Pioneers in Cell and Gene Therapy
Andelyn Biosciences is a cell and gene therapy development and contract manufacturing organization born out of Nationwide Children's Hospital, where the first FDA-approved systemic gene therapy was discovered.
Mission
Accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients.
Our Values are founded in our origin story.
The name “Andelyn” is a hybrid of two gene therapy pioneers who participated in pivotal Phase I clinical trials at Nationwide Children’s Hospital. Andrew received the first U.S. investigational gene therapy for Duchenne muscular dystrophy in 2006. Evelyn received experimental gene therapy for spinal muscular atrophy in 2015. “Andelyn” combines their names, representing all the families who have courageously participated in the research that make today’s gene therapies possible.
Collaborative.
Andelyn Biosciences is a partner to any organization working to improve human health, with scalable flexibility to adapt to our clients’ needs. A client partner might be a patient foundation searching for a cure. A Fortune 100 company starting Phase 3 trials. A university proposing an IND. Our state-of-the-art cGMP manufacturing facility is capable of early-stage development through commercial scale production.